Acute nephritic syndrome with diffuse membranous glomerulonephritis
Methodology & AI Transparency ⓘ
Acute nephritic syndrome with diffuse membranous glomerulonephritis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Acute nephritic syndrome with diffuse membranous glomerulonephritis uses ICD-10 N00.2 across Kidney & Renal specialty care.
- 3 Typical cash cost range: Primary evaluation for Acute nephritic syndrome with diffuse membranous glomerulonephritis incorporates spot urine albumin-to-creatinine in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: ratio) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Acute nephritic syndrome with diffuse membranous glomerulonephritis: Urine Albumin-to-Creatinine Ratio in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: (uACR)) (< 15 mg/g (< 30 mg/g normal) (N00.2)) and Serum Potassium, Bicarbonate in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: & Phosphorus).
Ask our AI Specialists anything about Acute nephritic syndrome with diffuse membranous glomerulonephritis
What Is Acute nephritic syndrome with diffuse membranous glomerulonephritis?
Recognized across U.S. clinical coding as N00.2 (Kidney & Renal), Acute nephritic syndrome with diffuse membranous glomerulonephritis is evaluated via spot urine albumin-to-creatinine in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: ratio) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in kidney & renal, Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2) involves impaired nephron solute/acid-base in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: clearance). progression correlates with shifts in Urine Albumin-to-Creatinine Ratio in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: (uACR)) (< 15 mg/g (< 30 mg/g normal) (N00.2)).
Common Symptoms & Clinical Signs
- • Presentation of Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2): changes in urine in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: output volume, nocturnal)
- • Secondary Acute nephritic syndrome with diffuse membranous glomerulonephritis clinical sign: asymptomatic decline in in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: eGFR or persistent)
- • Symptom flares in Acute nephritic syndrome with diffuse membranous glomerulonephritis correlating with Urine Albumin-to-Creatinine Ratio in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: (uACR)) deviation outside < 15 mg/g (< 30 mg/g normal) (N00.2)
- • Functional kidney & renal impact requiring spot urine albumin-to-creatinine in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: ratio) evaluation (N00.2)
Acute nephritic syndrome with diffuse membranous glomerulonephritis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N00.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N00.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N00.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Acute nephritic syndrome with diffuse membranous glomerulonephritis (N00.2: Cystatin C)) | >= 90 mL/min/1.73m2 (N00.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Acute nephritic syndrome with diffuse membranous glomerulonephritis
Treatment selection for Acute nephritic syndrome with diffuse membranous glomerulonephritis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acute nephritic syndrome with diffuse membranous glomerulonephritis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Intermittent or Continuous kidney-Replacement Therapy in Acute Kidney New England Journal of Medicine, Volume 395, Issue 17 , Page 1677-1690, October 29, 2026. New England Journal of Medicine • 2026-10-14 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID NEJM-62256824 ↗ |
| New Insights on Baseline data, initial course, and management: losartan versus captopril: What a 5,477-Participant Study Found A total of 5,477 patients with heart failure during the acute phase or with a new Q-wave anterior infarction or reinfarction were recruited. The American journal of cardiology • 2001-03-15 • Randomized Controlled Trial | N = 5,477 | 96/100 | PMID 11249900 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Evaluating the real-world benefits and safety of SpikoGen®, an: What a 4,219-Participant Study Found 12 657 and 4219 participants were randomized to the SpikoGen® and placebo group and followed for a median of 55 days (interquartile range, 48-60 days) and 51 days. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2023-02-15 • Phase III Randomized Trial | N = 4,219 | 96/100 | PMID 36096430 ↗ |
| New Insights on Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney: What a 6,385-Participant Study Found Results showed that statin loading before contrast administration was associated with a significantly reduced risk of CI-AKI in patients with CKD undergoing cardiac catheterization (odds ratio: 0.46; P < .05). Angiology • 2019-04-15 • Meta-Analysis | N = 6,385 | 94/100 | PMID 30261736 ↗ |
Acute nephritic syndrome with diffuse membranous glomerulonephritis Patient Community & “People Like Me” Threads
Filter Acute nephritic syndrome with diffuse membranous glomerulonephritis community threads and patient logs by age, biological sex, dosage, and treatment duration.